Alex Thompson
Stock Analyst at Stifel
(3.94)
# 617
Out of 5,124 analysts
41
Total ratings
63.64%
Success rate
9.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Buy | $254 → $256 | $213.24 | +20.05% | 4 | Dec 11, 2025 | |
| ARGX argenx SE | Maintains: Buy | $1,028 → $1,248 | $840.95 | +48.40% | 5 | Dec 11, 2025 | |
| ANAB AnaptysBio | Maintains: Buy | $80 → $56 | $48.48 | +15.51% | 2 | Dec 11, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $52 → $65 | $41.21 | +57.73% | 2 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $20 → $25 | $38.21 | -34.57% | 4 | Sep 12, 2025 | |
| CGEM Cullinan Therapeutics | Reinstates: Buy | $22 | $10.35 | +112.56% | 1 | Jun 11, 2025 | |
| KYMR Kymera Therapeutics | Reinstates: Buy | $55 | $77.81 | -29.32% | 1 | May 20, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $36 | $18.16 | +98.24% | 1 | Mar 25, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $60 | $46.55 | +28.89% | 1 | Mar 25, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $30.31 | +61.66% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 → $54 | $32.76 | +64.84% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $2 | $9.03 | -77.85% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $13.18 | +423.52% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $3.01 | -66.78% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $31.12 | +28.53% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $33.87 | +844.79% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $25.42 | +33.75% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.22 | +2,604.92% | 1 | Dec 14, 2022 |
Ascendis Pharma
Dec 11, 2025
Maintains: Buy
Price Target: $254 → $256
Current: $213.24
Upside: +20.05%
argenx SE
Dec 11, 2025
Maintains: Buy
Price Target: $1,028 → $1,248
Current: $840.95
Upside: +48.40%
AnaptysBio
Dec 11, 2025
Maintains: Buy
Price Target: $80 → $56
Current: $48.48
Upside: +15.51%
Dianthus Therapeutics
Sep 12, 2025
Maintains: Buy
Price Target: $52 → $65
Current: $41.21
Upside: +57.73%
Travere Therapeutics
Sep 12, 2025
Maintains: Hold
Price Target: $20 → $25
Current: $38.21
Upside: -34.57%
Cullinan Therapeutics
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $10.35
Upside: +112.56%
Kymera Therapeutics
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $77.81
Upside: -29.32%
Avalo Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $18.16
Upside: +98.24%
Crinetics Pharmaceuticals
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $46.55
Upside: +28.89%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $30.31
Upside: +61.66%
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $32.76
Upside: +64.84%
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $9.03
Upside: -77.85%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $13.18
Upside: +423.52%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $3.01
Upside: -66.78%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $31.12
Upside: +28.53%
Aug 9, 2023
Initiates: Buy
Price Target: $320
Current: $33.87
Upside: +844.79%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $25.42
Upside: +33.75%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.22
Upside: +2,604.92%